Physician profile
Edan Sarid
NPI 1700107208
$60,179.96
in general payments reported to CMS, 2019-2025
46 companies · $7,058 in 2025
The $7,058 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,821 · 2020: $5,504 · 2021: $6,731 · 2022: $16K · 2023: $6,186 · 2024: $16K · 2025: $7,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,393 · Consulting Fee: $1,582 · Travel and Lodging: $1,449 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,425.00 |
| Food and Beverage | $6,393.46 |
| Consulting Fee | $1,581.64 |
| Travel and Lodging | $1,448.87 |
| Education | $126.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51,541.52 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $2,277.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,151.70 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $792.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $509.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $387.05 | 2020-2025 | Glassia, Takhzyro |
| Biocryst US Sales Co., LLC | $359.89 | 2021-2025 | Orladeyo |
| Amgen INC. | $324.59 | 2022-2025 | Tezspire |
| Csl Behring | $312.34 | 2019-2025 | Andembry, Haegarda |
| Adma Biomanufacturing LLC | $293.00 | 2021-2023 | |
| Genentech USA, INC. | $265.54 | 2022-2025 | Xolair |
| Pharming Healthcare, INC. | $162.55 | 2021-2025 | |
| Cycle Pharmaceuticals INC | $162.12 | 2024-2025 | Sajazir |
| Abbvie INC. | $153.14 | 2020-2023 | Rinvoq |
| Pfizer INC. | $107.14 | 2019-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $106.08 | 2019-2025 | Prolastin-C Liquid |
| Ucb, INC. | $96.82 | 2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $96.67 | 2024-2025 | Purified Cortrophin Gel |
| Kaleo, INC. | $88.07 | 2021-2023 | Auvi-Q |
| Octapharma USA, INC. | $86.25 | 2022-2023 | Cutaquig, Panzyga |
| Endo Pharmaceuticals INC. | $85.56 | 2019-2020 | |
| Sobi, INC | $84.40 | 2023-2025 | |
| Incyte Corporation | $76.14 | 2022-2023 | Opzelura |
| Alexion Pharmaceuticals, INC. | $59.47 | 2024-2025 | Ultomiris |
| Lilly USA, LLC | $55.32 | 2025 | Ebglyss, Zepbound, Taltz |
| Janssen Biotech, INC. | $51.10 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $40.43 | 2020 | |
| Shire North American Group INC | $35.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.68 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $33.60 | 2019 | |
| Galderma Laboratories, L.P. | $33.06 | 2024 | |
| Organon LLC | $32.41 | 2025 | Vtama |
| Bio Products Laboratory USA, INC. | $31.88 | 2022-2023 | Coagadex, Gammaplex |
| Gc Biopharma USA, INC. | $30.84 | 2025 | Alyglo |
| Tonix Medicines, INC. | $25.32 | 2025 | Tonmya |
| Blueprint Medicines Corporation | $22.12 | 2023 | Ayvakit |
| Aimmune Therapeutics, INC. | $21.97 | 2022 | |
| Optinose US, INC. | $19.85 | 2024 | |
| Neos Therapeutics, LP | $19.57 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.67 | 2021 | |
| Aerin Medical INC. | $16.66 | 2021 | |
| Lundbeck LLC | $16.57 | 2022 | |
| Leo Pharma INC. | $15.74 | 2022 | |
| Boston Scientific Corporation | $14.85 | 2022 | |
| X4 Pharmaceuticals, INC. | $14.40 | 2024 | Xolremdi |
| Abbott Laboratories | $14.39 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edan Sarid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.